(19) &   

(11) EP 1 740 235 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61L 29/08 (2006.01) A61L 29/16 (2006.01) 22.07.2009 Bulletin 2009/30 A61L 31/10 (2006.01) A61L 31/16 (2006.01)

(21) Application number: 05744085.1 (86) International application number: PCT/US2005/011406 (22) Date of filing: 06.04.2005 (87) International publication number: WO 2005/099786 (27.10.2005 Gazette 2005/43)

(54) COATING COMPOSITIONS FOR BIOACTIVE AGENTS BESCHICHTUNGSZUSAMMENSETZUNGEN FÜR BIOAKTIVE MITTEL COMPOSITIONS DE REVETEMENT POUR AGENTS BIOACTIFS

(84) Designated Contracting States: • FINLEY, Michael, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR St. Louis Park, MN 55416 (US) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR • LAWIN, Laurie, R. New Brighton, MN 55112 (US) (30) Priority: 06.04.2004 US 559821 P • MALINOFF, Harrison, R. Golden Valley, MN 55427 (US) (43) Date of publication of application: 10.01.2007 Bulletin 2007/02 (74) Representative: Gowshall, Jonathan Vallance Forrester & Boehmert (73) Proprietor: SurModics, Inc. Pettenkoferstrasse 20-22 Eden Prairie, MN 55344-3523 (US) 80336 München (DE)

(72) Inventors: (56) References cited: • DEWITT, David, M. WO-A-01/87372 WO-A-03/105920 Minneapolis, MN 55401 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 740 235 B1

Printed by Jouve, 75001 PARIS (FR) EP 1 740 235 B1

Description

TECHNICAL FIELD

5 [0001] In one aspect, the present invention relates to a method of treating implantable medical devices with coating compositions to provide for the controlled release of bioactive (e.g., pharmaceutical) agents from the surface of the devices under physiological conditions. In another aspect, the invention relates to the coating compositions, per se. In yet another aspect, the invention relates to devices or surfaces coated with such compositions. In yet another aspect, the present invention relates to the local administration of bioactive agents for the prevention and treatment of diseases, 10 such as vascular and ocular diseases.

BACKGROUND OF THE INVENTION

[0002] Many surgical interventions require the placement of a medical device into the body. One prevalent surgical 15 intervention often requiring such a device is percutaneous transluminal coronary angioplasty ("PTCA"). Many individuals suffer from circulatory disease caused by a progressive blockage of the blood vessels, which often leads to hypertension, ischemic injury, stroke, or myocardial infarction. Percutaneous transluminal coronary angioplasty is a medical procedure performed to increase blood flow through a damaged artery and is now the predominant treatment for coronary vessel stenosis. The increasing use of this procedure is attributable to its relatively high success rate and its minimal invasiveness 20 compared with coronary bypass surgery. A limitation associated with PTCA is the abrupt closure of the vessel which can occur soon after angioplasty. Insertion of small spring-like medical devices called stents into such damaged vessels has proved to be a better approach to keep the vessels open as compared to systemic pharmacologic therapy. [0003] While often necessary and beneficial for treating a variety of medical conditions, metal or polymeric devices (e.g., stents, catheters...), after placement in the body, can give rise to numerous physiological complications. Some of 25 these complications include: increased risk of infection; initiation of a foreign body response resulting in inflammation and fibrous encapsulation; and initiation of a detrimental wound heal